Created On: 2020-07-15
Record Count: 8
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 995
IPSCIO Record ID: 27897
IPSCIO Record ID: 152350
Bucindolol means the compound Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-imethylethyl]amino]propoxy]-, monohydrochloride, also known under the trademark 'BEXTRA'.
Bucindolol Intellectual Property means the Trademarks and any patents, patent applications, copyrights, know-how, processes, formulae, data (including, but not limited to, preclinical, clinical, and marketing data) and trade secrets relating to the manufacture, development, commercialization or use of Bucindolol including any Improvement made or acquired by Licensor during the term of this Agreement.
BEAT means the Bucindolol Evaluation in Acute Myocardial Infarction Trial being conducted by Knoll.
BEST means the 'Beat-blocker Evaluation of Survival Trial' being conducted by the National Institutes of Health and the Veterans Administration, evaluating the use of Bucindolol in treating patients with congestive heart failure.
Trademark means the registered trademark BEXTRA(R), any other trademark, trade name or service mark used as a product identifier for Bucindolol and any variations thereof, in each case, whether or not registered.
IPSCIO Record ID: 178134
IPSCIO Record ID: 27836
IPSCIO Record ID: 26860
IPSCIO Record ID: 28684
The Merger Agreement requires the Licensee to pay certain earn out payments following the first commercial sale of AMR-001 for the benefit of the former stockholders of the Licensor.
IPSCIO Record ID: 25875
Under the Agreement, the Licensee will have the exclusive rights to market the treatment of chronic heart failure and other cardiovascular conditions. The technology has received European Union regulatory approval as a medical device under the CE Mark, which enables marketing of the product for the treatment of chronic heart failure in the 27 member countries of the European Union. The Licensee has also acquired the right of first negotiation with respect to the remaining countries of the EU. Under the Agreement, the commercial launch strategy in Europe will involve an initial commercialization phase during which the Licensee will target key opinion leaders in the major markets of Europe to ensure support for expanded use within the broader cardiology community.
Celacade is a non-pharmacological treatment also known as Immune Modulation Therapy (IMT). This therapy is using a modified sample of a patient's own blood to trick the immune system into fighting cardiac inflammation. Celcade is a device-based outpatient procedure involving ex vivo exposure of 10ml autologous blood to heat, ultraviolet irradiation, controlled oxidative ozone therapy and subsequent intramuscular administration at monthly intervals.